364 related articles for article (PubMed ID: 24376723)
1. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
[TBL] [Abstract][Full Text] [Related]
3. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
[TBL] [Abstract][Full Text] [Related]
5. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.
Buttitta F; Felicioni L; Del Grammastro M; Filice G; Di Lorito A; Malatesta S; Viola P; Centi I; D'Antuono T; Zappacosta R; Rosini S; Cuccurullo F; Marchetti A
Clin Cancer Res; 2013 Feb; 19(3):691-8. PubMed ID: 23243218
[TBL] [Abstract][Full Text] [Related]
6. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Marchetti A; Del Grammastro M; Felicioni L; Malatesta S; Filice G; Centi I; De Pas T; Santoro A; Chella A; Brandes AA; Venturino P; Cuccurullo F; Crinò L; Buttitta F
PLoS One; 2014; 9(8):e103883. PubMed ID: 25137181
[TBL] [Abstract][Full Text] [Related]
7. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
[TBL] [Abstract][Full Text] [Related]
9. Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.
Righi L; Cuccurullo A; Vatrano S; Cappia S; Giachino D; De Giuli P; Ardine M; Novello S; Volante M; Scagliotti GV; Papotti M
BMC Cancer; 2013 Mar; 13():114. PubMed ID: 23497146
[TBL] [Abstract][Full Text] [Related]
10. Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer.
Lechner A; Rai A; Rojas-Rudilla V; Kuang Y; Paweletz CP; Sholl LM; Dong F
Arch Pathol Lab Med; 2024 May; 148(5):553-558. PubMed ID: 37639432
[TBL] [Abstract][Full Text] [Related]
11. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
Wang X; Wang G; Hao Y; Xu Y; Zhang L
Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
[TBL] [Abstract][Full Text] [Related]
12. Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations.
Vliegen L; Dooms C; De Kelver W; Verbeken E; Vansteenkiste J; Vandenberghe P
Diagn Pathol; 2015 May; 10():57. PubMed ID: 26022577
[TBL] [Abstract][Full Text] [Related]
13. Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction.
Kanaji N; Bandoh S; Ishii T; Kushida Y; Haba R; Kohno K; Dobashi H; Ohnishi H; Matsunaga T
Mol Diagn Ther; 2011 Dec; 15(6):353-9. PubMed ID: 22117119
[TBL] [Abstract][Full Text] [Related]
14. Detection of
Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
[TBL] [Abstract][Full Text] [Related]
15. Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.
Delgado-García M; Weynand B; Gómez-Izquierdo L; Hernández MJ; Blanco ÁM; Varela M; Matias-Guiu X; Nadal E; Márquez-Lobo B; Alarcão A; de Álava E; Biscuola M
BMC Cancer; 2020 Apr; 20(1):275. PubMed ID: 32245434
[TBL] [Abstract][Full Text] [Related]
16. [Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer - is there a "golden standard" in diagnostics?].
Skroński M; Szpechciński A; Chorostowska-Wynimko J
Pneumonol Alergol Pol; 2014; 82(3):311-22. PubMed ID: 24793156
[TBL] [Abstract][Full Text] [Related]
17. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
[TBL] [Abstract][Full Text] [Related]
18. EGFR Mutational Profiling in Non-Small Cell Lung Cancer: The Clinical Performance of a Sensitive Reverse-Hybridization Assay.
Kriegshäuser G; Enko D; Novy M; Reitmayr A; Loidl A; Halwachs-Baumann G; Oberkanins C
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):388-392. PubMed ID: 27801728
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
[TBL] [Abstract][Full Text] [Related]
20. A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.
Beau-Faller M; Blons H; Domerg C; Gajda D; Richard N; Escande F; Solassol J; Denis MG; Cayre A; Nanni-Metellus I; Olschwang S; Lizard S; Piard F; Pretet JL; de Fraipont F; Bièche I; de Cremoux P; Rouquette I; Bringuier PP; Mosser J; Legrain M; Voegeli AC; Saulnier P; Morin F; Pignon JP; Zalcman G; Cadranel J
J Mol Diagn; 2014 Jan; 16(1):45-55. PubMed ID: 24183959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
